Mazdutide
LY3305677 / IBI362
Mazdutide (LY3305677/IBI362) is a GLP-1/glucagon receptor dual agonist co-developed by Innovent Biologics and Eli Lilly, primarily advancing through clinical development in China. It activates both GLP-1 receptors for appetite suppression and glucagon receptors for enhanced energy expenditure and hepatic fat reduction. The compound is in Phase 3 clinical trials for obesity and type 2 diabetes in the Chinese market.
Mecanismo de Acción
Dual GLP-1/glucagon receptor agonist. Promotes direct hepatic fat oxidation and thermogenesis alongside appetite suppression.
Protocolos de Investigación
Para propósitos de investigación solo. No es asesoramiento médico.
Phase 3 research protocols use 4mg to 9mg biweekly subcutaneous injection.
Notas de Investigación
Clinical Research Status
Mazdutide has completed multiple Phase 3 trials in China, with regulatory submission to China's NMPA anticipated or underway. The GLORY Phase 3 program demonstrated up to 14.4% body weight loss at 48 weeks in Chinese patients with obesity. Innovent holds rights for the Chinese market while Eli Lilly retains rights for other territories, though global development timelines remain less defined.
Key Published Findings
Phase 2/3 data showed dose-dependent weight loss with the 6mg and 9mg doses demonstrating the strongest efficacy. The glucagon receptor component is hypothesized to increase energy expenditure and promote hepatic lipid oxidation beyond what GLP-1 agonism alone achieves. HbA1c reductions of 1.5-2.0% have been observed in diabetic populations, suggesting robust dual metabolic benefit.
Safety Profile
Gastrointestinal adverse events remain the most common class effect, with nausea and diarrhea reported in 20-40% of patients during titration. The glucagon component raises theoretical concerns about hepatic glucose output, though hyperglycemia has not emerged as a significant finding in clinical data. Heart rate increases have been observed, consistent with GLP-1 agonist class effects, and long-term cardiovascular outcome data is not yet available.
Comparison to Related Compounds
Mazdutide shares the dual GLP-1/glucagon mechanism with survodutide (Boehringer Ingelheim) but has advanced further in regulatory timelines within China. Unlike tirzepatide which targets GIP/GLP-1, mazdutide's glucagon component is designed to boost energy expenditure rather than enhance incretin signaling. The weight loss magnitude appears intermediate between semaglutide monotherapy and the highest tirzepatide doses.
Community Observations
Mazdutide represents one of the most advanced obesity therapeutics developed primarily for the Asian market, where metabolic disease prevalence is rising rapidly. Researchers note the glucagon component may offer particular benefit for NAFLD/MASH given glucagon's role in hepatic fat metabolism. The compound's development trajectory illustrates the growing importance of the Chinese pharmaceutical market for peptide therapeutics.
Media Vida
~5-6 days
Reconstitución
Bacteriostatic water (BAC)
Almacenamiento
Liofilizado
Refrigerate 2-8C. Protect from light.
Reconstituído
Refrigerate 2-8C. Use within 21 days.
Estado Legal EE.UU.
También Se Conoce Como
Última Investigación
Preguntas frecuentes
¿Qué es Mazdutide?
Mazdutide (LY3305677/IBI362) is a GLP-1/glucagon receptor dual agonist co-developed by Innovent Biologics and Eli Lilly, primarily advancing through clinical development in China. It activates both GLP-1 receptors for appetite suppression and glucagon receptors for enhanced energy expenditure and hepatic fat reduction. The compound is in Phase 3 clinical trials for obesity and type 2 diabetes in the Chinese market.
¿Cómo funciona Mazdutide?
Dual GLP-1/glucagon receptor agonist. Promotes direct hepatic fat oxidation and thermogenesis alongside appetite suppression.
¿Cuál es el estado regulatorio de Mazdutide en EE. UU.?
Research chemical (not FDA-approved)
¿Cuál es la vida media de Mazdutide?
~5-6 days
¿Qué otros nombres tiene Mazdutide?
LY3305677, IBI362
Peptide Contacts proporciona resúmenes basados en investigaciones únicamente para fines informativos. No hospedamos, distribuimos ni endosamos la documentación del proveedor. Todos los certificados de análisis, certificados GMP y comunicaciones del proveedor deben solicitarse y verificar directamente por el comprador. Nada en esta plataforma constituye asesoramiento legal, médico o profesional. Los usuarios son únicamente responsables de verificar las credenciales del proveedor y asegurarse de cumplir con todas las leyes locales, estatales y federales aplicables antes de comprar cualquier químico de investigación. El uso de esta plataforma constituye aceptación de toda la responsabilidad personal.
Leer aviso completo